Repeat Drug Treatment of Endometriosis Without Lasting Bone Loss

Pja Hillard

doi:10.1056/wh199802010000009

Repeat Drug Treatment of Endometriosis Without Lasting Bone Loss

Pja Hillard

In: Journal watch · 1998 · vol. 1998 · doi:10.1056/wh199802010000009 · W2259492736

article OA: closed CC0

View on OpenAlex View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-28 ⓘ

This study investigated repeat drug treatment for endometriosis with GnRH agonists, assessing its safety regarding bone loss beyond the FDA-approved six-month duration.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Treatment of endometriosis with gonadotropin-releasing hormone (GnRH) agonist analogs is currently approved by the FDA for only six months because of

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel) 1997

References (1)

Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel) via openalex

Source provenance

openalex: last seen: 2026-06-10T17:14:06.276822+00:00

License: CC0 · commercial use OK

[1] Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel) 1997